Hypothesis

Combining intermittent dasatinib plus quercetin (D+Q) senolytic therapy with chronologically timed omega-3 polyunsaturated fatty acid (PUFA) supplementation will produce a greater reduction in senescence-associated secretory phenotype (SASP) factors and NLRP3 inflammasome activation than either intervention alone, leading to measurable improvements in immune function and frailty markers in older adults.

Rationale

Senolytics clear senescent cells, decreasing the source of SASP cytokines that drive chronic inflammation [1][2][3]. Omega-3 PUFAs inhibit NF‑κB signaling and serve as precursors for specialized pro‑resolving mediators that actively dampen inflammasome activity [7]. Recent work shows SASP can prime the NLRP3 inflammasome, creating a feed‑forward loop that amplifies IL‑1β and IL‑18 release [4]. By removing senescent cells with D+Q and simultaneously providing omega‑3s that block NLRP3 activation and promote resolution, we predict a synergistic break of this loop.

Mechanistically, senescent cell clearance reduces upstream DAMPs (e.g., mitochondrial DNA) that trigger NLRP3 [6]. Omega‑3‑derived resolvins then enhance macrophage efferocytosis, clearing apoptotic debris and preventing secondary necrosis that would otherwise reignite inflammasome signaling. This two‑pronged approach targets both the source and the amplification platform of inflammaging.

Predictions

1. Serum levels of IL‑6, TNF‑α, IL‑1β, and IL‑18 will decline more sharply in the combination group than in monotherapy or placebo groups after 12 weeks.
2. Peripheral blood mononuclear cells will show reduced NLRP3 inflammasome activation (measured by ASC speck formation) ex vivo.
3. Thymic output, assessed by T‑cell receptor excision circles (TRECs), will increase significantly only in the combination arm, reflecting reversal of immunosenescent thymic involution [7].
4. Frailty index scores will improve by ≥15 % in the combination group, outperforming the ≤5 % change expected from monotherapies.
5. Adverse event rates will remain comparable to those reported for D+Q alone, indicating safety of the add‑on omega‑3 regimen.

Experimental Design

A double‑blind, randomized, placebo‑controlled trial with four arms (n=50 per arm) in adults aged 65‑80:

• Arm A: Placebo for both D+Q and omega‑3.
• Arm B: Intermittent D+Q (dasatinib 5 mg/kg + quercetin 50 mg/kg orally once weekly for three weeks every four weeks) + placebo omega‑3.
• Arm C: Placebo D+Q + high‑dose omega‑3 (2 g EPA/DHA daily).
• Arm D: Intermittent D+Q + high‑dose omega‑3 (same dosing as arms B and C). Primary endpoints: change in multiplex inflammatory cytokine panel and NLRP3 activation assay at baseline, 6 weeks, and 12 weeks. Secondary endpoints: TREC frequency, frailty index, physical performance (Short Physical Performance Battery), and safety labs. Statistical analysis will use mixed‑effects models to test interaction between senolytic and omega‑3 treatments; a significant interaction term supporting greater‑than‑additive effects will confirm the hypothesis.

If the combination fails to show superior biomarker reduction or functional improvement relative to the best monotherapy, the hypothesis is falsified, indicating that senescent cell clearance and omega‑3 mediated inflammasome inhibition do not synergize in humans as predicted.